Prognostic impact of combined fludarabine, treosulfan and mitoxantrone resistance profile in childhood acute myeloid leukemia

Anticancer Research

Volumn 28, Issue 3 B, 2008, Pages 1927-1931

  Styczynski, Jan ^a   Wysocki, Mariusz ^a   Dluzniewska, Agnieszka ^b   Juraszewska, Edyta ^b   Balwierz, Walentyna ^b   Czyzewski, Krzysztof ^a   Wieczorek, Maria ^c   Olejnik, Igor ^c   Krawczuk Rybak, Maryna ^d   Kuzmicz, Marta ^d   Kowalczyk, Jerzy ^e   Stefaniak, Jolanta ^e   Badowska, Wanda ^f   Sonta Jakimczyk, Danuta ^g   Szczepanski, Tomasz ^g   Matysiak, Michal ^h   Stanczak, Elzbieta ^h   Malinowska, Iwona ^h   Wachowiak, Jacek ⁱ   Konatkowska, Benigna ⁱ   Gil, Lidia ⁱ   Balcerska, Anna ^j   Kapuscinska, Lucyna ^j   Szczepanek, Joanna ^a   Kolodziej, Beata ^a   Rafinska, Beata ^a   Kubicka, Malgorzata ^a   more..

^a NICOLAUS COPERNICUS UNIVERSITY   (Poland)

^b JAGIELLONIAN UNIVERSITY MEDICAL COLLEGE   (Poland)

^c Pediatric Center   (Poland)

^d MEDICAL UNIVERSITY OF BIALYSTOK   (Poland)

^e MEDICAL UNIVERSITY OF LUBLIN   (Poland)

^f Children Hospital   (Poland)

^g Medical University   (Poland)

^h MEDICAL UNIVERSITY OF WARSAW   (Poland)

ⁱ POZNAN UNIVERSITY OF MEDICAL SCIENCES   (Poland)

^j MEDICAL UNIVERSITY OF GDANSK   (Poland)

more..

Author keywords

Acute myeloid leukemia; Children; Drug resistance; Drug sensitivity; Prognostic factors

Indexed keywords

ASPARAGINASE; CARBOPLATIN; CISPLATIN; CLADRIBINE; COSMOGEN; CYCLOPHOSPHAMIDE; CYTARABINE; DACTINOMYCIN; DAUNORUBICIN; DEXAMETHASONE; DOCETAXEL; DOXORUBICIN; EPIRUBICIN; ETOPOSIDE; FLUDARABINE PHOSPHATE; IDARUBICIN; IFOSFAMIDE; MAFOSFAMIDE; MELPHALAN; MERCAPTOPURINE; MITOMYCIN D; MITOXANTRONE; PACLITAXEL; PLATIDAM; PREDNISOLONE; TENIPOSIDE; THIOTEPA; TIOGUANINE; TREOSULFAN; VINCRISTINE; VINCRISTINE SULFATE; VINDESINE;

ACUTE GRANULOCYTIC LEUKEMIA; ARTICLE; BLAST CELL; CANCER COMBINATION CHEMOTHERAPY; CANCER RELAPSE; CHEMOSENSITIVITY; CHILD; CHILDHOOD LEUKEMIA; COHORT ANALYSIS; COMBINATION CHEMOTHERAPY; DISEASE FREE SURVIVAL; DRUG CYTOTOXICITY; FEMALE; FOLLOW UP; HUMAN; HUMAN CELL; IN VITRO STUDY; LEUKEMIA CELL; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS; TREATMENT OUTCOME;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BUSULFAN; CHILD; CHILD, PRESCHOOL; COHORT STUDIES; DRUG RESISTANCE, NEOPLASM; DRUG SCREENING ASSAYS, ANTITUMOR; FEMALE; HUMANS; INFANT; LEUKEMIA, MYELOID, ACUTE; MALE; MITOXANTRONE; PROGNOSIS; VIDARABINE;

EID: 45949090607     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. Kaspers GJ and Creutzig U: Pediatric acute myeloid leukemia: international progress and future directions. Leukemia 19: 2025-2029, 2005.
2. Kaspers GJ, Zwaan CM, Veerman AJ, Rots MG, Pieters R, Bucsky P, Domula M, Gobel U, Graf N, Havers W, Jorch N, Kabisch K, Spaar HJ, Ritter J and Creutzig U: Cellular drug resistance in acute myeloid leukemia: literature review and preliminary analysis of an ongoing collaborative study. Klin Padiatr 211: 239-244, 1999.
3. Creutzig U, Zimmermann M, Ritter J, Reinhardt D, Hermann J, Henze G, Jurgens H, Kabisch H, Reiter A, Riehm H, Gadner H and Schellong G: Treatment strategies and long-term results in paediatric patients treated in four consecutive AML-BFM trials. Leukemia 19: 2030-2042, 2005.
4. Kardos G, Zwaan CM, Kaspers GJ, de-Graaf SS, de Bont ES, Postma A, Bokkerink JP, Weening RS, van der Does-van den Berg A, van Wering ER, Korbijn C and Hahlen K: Treatment strategy and results in children treated on three Dutch Childhood Oncology Group acute myeloid leukemia trials. Leukemia 19: 2063-2071, 2005.
5. Ravindranath Y, Chang M, Steuber CP, Becton D, Dahl G, Civin C, Camitta B, Carroll A, Raimondi SC and Weinstein HJ: Pediatric Oncology Group (POG) studies of acute myeloid leukemia (AML): a review of four consecutive childhood AML trials conducted between 1981 and 2000. Leukemia 19: 2101-2116, 2005.
6. Dluzniewska A, Balwierz W, Armata J, Balcerska A, Chybicka A, Kowalczyk J, Matysiak M, Ochocka M, Radwanska U, Rokicka-Milewska R, Sonta-Jakimczyk D, Wachowiak J and Wysocki M: Twenty years of Polish experience with three consecutive protocols for treatment of childhood acute myelogenous leukemia. Leukemia 19: 2117-2124, 2005.
7. Ribeiro RC, Razzouk BI, Pounds S, Hijiya N, Pui CH and Rubnitz JE: Successive clinical trials for childhood acute myeloid leukemia at St Jude Children's Research Hospital, from 1980 to 2000. Leukemia 19: 2125-2129, 2005.
8. Gibson BE, Wheatley K, Hann IM, Stevens RF, Webb D, Hills RK, De Graaf SS and Harrison CJ: Treatment strategy and long-term results in paediatric patients treated in consecutive UK AML trials. Leukemia 19: 2130-2138, 2005.
9. Den Boer ML, Harms DO, Pieters R, Kazemier KM, Gobel U, Korholz D, Graubner U, Haas RJ, Jorch N, Spaar HJ, Kaspers GJ, Kamps WA, Van der Does-Van den Berg A, Van Wering ER, Veerman AJ and Janka-Schaub GE: Patient stratification based on prednisolone-vincristine-asparaginase resistance profiles in children with acute lymphoblastic leukemia. J Clin Oncol 21: 3262-3268, 2003.
10. Styczynski J and Wysocki M: Is the in vitro drug resistance profile the strongest prognostic factor in childhood acute lymphoblastic leukemia? J Clin Oncol 22: 963-964, 2004.
11. Styczynski J and Wysocki M: Ex vivo modulation of response to prednisolone in childhood acute lymphoblastic leukaemia. Br J Haematol 133: 397-399, 2006.
12. Smith PJ and Lihou MG: Prediction of remission induction in childhood acute myeloid leukemia. Aust NZ J Med 16: 39-42, 1986.
13. Dow LW, Dahl GV, Kalwinsky DK, Mirro J, Nash MB and Roberson PK: Correlation of drug sensitivity in vitro with clinical responses in childhood acute myeloid leukemia. Blood 68: 400-405, 1986.
14. Rosanda C, Garaventa A, Pasino M, Strigini P and De Bernardi B: A short-term in vitro drug sensitivity assay in pediatric malignancies. Anticancer Res 7: 365-367, 1987.
15. Klumper E, Pieters R, Kaspers GJ, Huismans DR, Loonen AH, Rottier MM, van Wering ER, van der Does-van den Berg A, Hahlen K and Creutzig U: In vitro chemosensitivity assessed with the MTT assay in childhood acute non-lymphoblastic leukemia. Leukemia 9: 1864-1869, 1995.
16. Miller CB, Zehnbauer BA, Piantadosi S, Rowley SD and Jones RJ: Correlation of occult clonogenic leukemia drug sensitivity with relapse after autologous bone marrow transplantation. Blood 78: 1125-1131, 1991.
17. Zwaan CM, Kaspers GJ, Pieters R, Ramakers-Van Woerden NL, den Boer ML, Wunsche R, Rottier MM, Hahlen K, van Wering ER, Janka-Schaub GE, Creutzig U and Veerman AJ: Cellular drug resistance profiles in childhood acute myeloid leukemia: differences between FAB types and comparison with acute lymphoblastic leukemia. Blood 96: 2879-2886, 2000.
18. Zwaan CM, Kaspers GJ, Pieters R, Hahlen K, Janka-Schaub GE, van Zantwijk CH, Huismans DR, de Vries E, Rots MG, Peters GJ, Jansen G, Creutzig U and Veerman AJ: Different drug sensitivity profiles of acute myeloid and lymphoblastic leukemia and normal peripheral blood mononuclear cells in children with and without Down syndrome. Blood 99: 245-251, 2002.
19. Yamada S, Hongo T, Okada S, Watanabe C, Fujii Y and Ohzeki T: Clinical relevance of in vitro chemoresistance in childhood acute myeloid leukemia. Leukemia 15: 1892-1897, 2001.
20. Staib P, Staltmeier E, Neurohr K, Cornely O, Reiser M and Schinkothe T: Prediction of individual response to chemotherapy in patients with acute myeloid leukaemia using the chemosensitivity index Ci. Br J Haematol 128: 783-791, 2005.
21. Styczynski J, Toporski J, Wysocki M, Debski R, Chybicka A, Boruczkowski D, Wachowiak J, Wojcik B, Kowalczyk J, Gil L, Balwierz W, Matysiak M, Krawczuk-Rybak M, Balcerska A and Sonta-Jakimczyk D: Fludarabine, treosulfan and etoposide sensitivity and the outcome of hematopoietic stem cell transplantation in childhood acute myeloid leukemia. Anticancer Res 27: 1547-1551, 2007.
22. Gil L, Styczynski J, Dytfeld D, Debski R, Kazmierczak M, Kolodziej B, Rafinska B, Kubicka M, Nowicki A, Komarnicki M and Wysocki M: Activity of bortezomib in adult de novo and relapsed acute myeloid leukemia. Anticancer Res 27: 4021-4026, 2007.
23. Pieters R, Huismans DR, Loonen AH, Hahlen K, van der Does-van den Berg A, van Wering ER and Veerman AJ: Relation of cellular drug resistance to long-term clinical outcome in childhood acute lymphoblastic leukaemia. Lancet 338: 399-403, 1991.
24. Zwaan CM and Kaspers GJ: Possibilities for tailored and targeted therapy in paediatric acute myeloid leukaemia. Br J Haematol 127: 264-279, 2004.
25. Zwaan CM, Kaspers GJ, Pieters R, Hahlen K, Huismans DR, Zimmermann M, Harbott J, Slater RM, Creutzig U and Veerman AJ: Cellular drug resistance in childhood acute myeloid leukemia is related to chromosomal abnormalities. Blood 100: 3352-3360, 2002.